IHL — Incannex Healthcare Share News
0.000.00%
Last trade - 00:00HealthcareSpeculativeMicro Cap
- AU$65.07m
- AU$31.87m
- AU$1.38m
Brief: Incannex Healthcare Says Federal Court Of Australia Approved Proposed Schemes Of Arrangement Between Incannex And Its Shareholders
Australia's Incannex up as shareholders in favour of US redomicile
Brief: Incannex Healthcare Will Prepare FDA Ind Application PSI-Gad
Brief: Review Of Ind Application For Ihl-42X By Us FDA Has Been Completed Clinical Trial For Patients With Obstructive Sleep Apnoea May Proceed
Brief: Incannex Healthcare Says Review Of IND Application For Ihl-42X By US FDA Has Been Completed
Brief: Incannex Healthcare Completes Positive Pre-IND Meeting With US FDA On IHL-675A
Brief: Incannex Submits IND Application To The US FDA For IHL-42X For Obstructive Sleep Apnoea
Brief: Incannex Receives Hrec Approval For Phase 2 Clinical Trial Assessing Ihl-675A For Use In Treatment Of Pain And Function In Rheumatoid Arthritis
Brief: Incannex Healthcare Announces Intention To Redomicile To United States
Australia's Incannex Healthcare up on nod for clinical trial of sleep apnoea drug
Brief: Incannex Healthcare Says Received Approval From Bellberry Human Research Ethics Committee
Brief: Incannex Appoints Principal Investigators For IHL-42X Phase 2/3 Clinical Trial
Brief: Incannex Enters A Lease For First Psychedelic-Assisted Psychotherapy Clinic
Brief: Incannex Announces Final Results From Phase 1 Clinical Trial Assessing Safety And Pharmacokinetics Of IHL-675A
Brief: Incannex Appoints Qps To Advance Cannquit-N, Cannquit-O & Renecann Products In US & EU
Brief: Incannex To Commercialise Its Psychedelic Clinics Business In Collaborative Partnership With Leading Psychedelic Experts
Australia's Incannex rises on positive interim data for anxiety therapy
Brief: Interim Review Of Proprietary PsiGAD Clinical Trial Data Indicates No Safety Concerns
Brief: Incannex Healthcare Seeks Trading Halt